Phrontline Biopharma Suzhou closed a $60 million pre-A+ financing round led by Lapam Investment to advance its bispecific antibody-drug conjugate (ADC) programs built on dual-linker payload and bispecific antibody platforms. The capital will support preclinical and IND-enabling work for next-generation ADC candidates targeting solid tumors, including expansion of manufacturing and R&D in Suzhou. The financing reflects growing investor appetite for ADC innovation — particularly bispecific formats aiming to enhance tumor selectivity and reduce systemic toxicity. Phrontline plans to use funds for candidate optimization and to prepare global development strategies; strategic partners and regulatory timelines will determine speed to clinic.